2011
DOI: 10.1016/j.bbrc.2011.03.109
|View full text |Cite
|
Sign up to set email alerts
|

Bone morphogenetic protein (BMP)1-3 enhances bone repair

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
39
0
5

Year Published

2011
2011
2019
2019

Publication Types

Select...
6
3

Relationship

3
6

Authors

Journals

citations
Cited by 67 publications
(44 citation statements)
references
References 27 publications
(24 reference statements)
0
39
0
5
Order By: Relevance
“…Recently, mTLD was reported to as a component of human plasma (37), although with a size of 95 kDa, smaller than the 130 kDa previously reported for mTLD (11,23). Thus, mTLD or an mTLD derivative may exert systemic effects, in addition to localized effects exerted by mTLD produced in individual tissues.…”
Section: B/tp Distributions and General Functionsmentioning
confidence: 70%
See 1 more Smart Citation
“…Recently, mTLD was reported to as a component of human plasma (37), although with a size of 95 kDa, smaller than the 130 kDa previously reported for mTLD (11,23). Thus, mTLD or an mTLD derivative may exert systemic effects, in addition to localized effects exerted by mTLD produced in individual tissues.…”
Section: B/tp Distributions and General Functionsmentioning
confidence: 70%
“…Thus, mTLD or an mTLD derivative may exert systemic effects, in addition to localized effects exerted by mTLD produced in individual tissues. Circulating mTLD appears to be involved in bone fracture repair and in the fibrosis associated with chronic kidney disease (37,39). Thus, inhibition or provision of circulating mTLD may represent future approaches to therapeutic interventions in these and related conditions.…”
Section: B/tp Distributions and General Functionsmentioning
confidence: 99%
“…(250 ug/kg, 2x/wk) and BMP1-3 (3 ug, 3x/wk) +BMP6 i.v. (250 μg, 2x/wk) therapy (mean±SD, n=6) [234]. D. Outline of a hypothetical experiment in which tested treatment (T) and a control (Ctr) are assessed ex-vivo at two time points (1, 2) around midtime of the spontaneous healing process.…”
Section: Non-critical Size Defectmentioning
confidence: 99%
“…In contrast, injection of specific polyclonal antibody and endogenous BMPs-1-3 led to delayed bone junction. The in vitro experiments found that BMPs-1-3 can enhance the expression levels of type-I collagen and osteocalcin in osteoclasts MC3T3-E1 and stimulate the formation of mineralized bone knot of mesenchymal stem cells [61].…”
Section: Interactions Between Bmp-1 and Bmps Family Membersmentioning
confidence: 99%